Jefferies Financial Group’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.58M Sell
39,620
-4,731
-11% -$396K 0.02% 487
2026
Q1
$3.55M Buy
44,351
+18,762
+73% +$1.55M 0.02% 425
2025
Q4
$2.18M Sell
25,589
-26,911
-51% -$2.21M 0.01% 773
2025
Q3
$4.08M Buy
+52,500
New +$4.1M 0.02% 431
2025
Q2
– Sell
-41,969
Closed -$3.04M – 1468
2025
Q1
$3.04M Sell
41,969
-8,769
-17% -$628K 0.03% 442
2024
Q4
$3.76M Sell
50,738
-40,964
-45% -$2.87M 0.02% 455
2024
Q3
$6.05M Buy
91,702
+51,202
+126% +$3.72M 0.04% 269
2024
Q2
$3.74M Sell
40,500
-69,087
-63% -$6.12M 0.04% 373
2024
Q1
$10.5M Sell
109,587
-68,726
-39% -$5.77M 0.1% 165
2023
Q4
$13.6M Buy
178,313
+171,304
+2,444% +$11.9M 0.09% 166
2023
Q3
$486K Buy
7,009
+4,790
+216% +$385K ﹤0.01% 1075
2023
Q2
$209K Sell
2,219
-44,481
-95% -$3.87M ﹤0.01% 1416
2023
Q1
$3.86M Buy
+46,700
New +$3.67M 0.03% 437

Other funds holding EW

Jefferies Financial Group's EW Position: Q2 2026 in Review

Jefferies Financial Group reduced its Edwards Lifesciences (EW) stake by 11% in Q2 2026, selling an estimated $396K and leaving 39,620 shares worth $3.58M. The position accounts for 0.02% of the portfolio, ranked #487.

Jefferies Financial Group first reported a position in EW in Q1 2023 and has held it in 13 quarters since. The position peaked at $13.6M in Q4 2023. 1,337 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Jefferies Financial Group held 39,620 shares of Edwards Lifesciences worth $3.58M as of Q2 2026.
  • Jefferies Financial Group sold 4,731 Edwards Lifesciences shares in Q2 2026, an estimated $396K.
  • Edwards Lifesciences made up 0.02% of Jefferies Financial Group's portfolio in Q2 2026, its #487 holding.
  • Jefferies Financial Group first reported a position in Edwards Lifesciences in Q1 2023 and has held it in 13 quarters since.
  • Jefferies Financial Group's Edwards Lifesciences position peaked at $13.6M in Q4 2023.
  • 1,337 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.